The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...
ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA filing planned for 2026.
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...
104.5 WOKV on MSN
Local hospital gets new technology to perform non-invasive procedure to remove liver cancer
A local hospital is using new technology to remove liver cancer without invasive surgery.
A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...
Landmark trials have driven a shift from radical mastectomies to less invasive, breast-conserving surgeries. Non-invasive breast carcinomas, when detected early, have highly favorable survival and ...
Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...
ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results